Will GALEN become more RELEVANT?
Mené sur 89 patients traités pour un lymphome folliculaire à cellules B réfractaire ou récidivant, cet essai multicentrique de phase II évalue l'efficacité, du point de vue de la proportion de patients répondant au traitement, et la toxicité d'un traitement d'induction combinant obinutuzumab et lénalidomide (durée médiane de suivi : 2,6 ans)
Remarkable strides have been made in the treatment of patients with follicular lymphoma over the past two decades with the discovery of the anti-CD20 monoclonal antibody rituximab, ushering a new phase of second-generation type 2 glycoengineered anti-CD20 antibodies, such as ofatumomab and obinutuzomab. Attempts to further improve outcomes while decreasing both short-term and long-term toxicities have led to the development of chemotherapy-free approaches, including targeted therapy. To date, three different phosphoinositide 3'-kinase (PI3K) inhibitors have been approved by regulatory agencies for the treatment of patients with relapsed follicular lymphoma. These advances have contributed to the increase in the median overall survival of patients with follicular lymphoma now exceeding 20 years